Our team is made up of over 80 individuals who design and conduct multi-center clinical trials, especially for neurodegenerative and rare disorders. Over the last two decades, CHeT has been instrumental in conducting pivotal clinical trials in support of seven FDA approvals. These include first of their kind therapies for Parkinson disease, Huntington disease, and other rare disorders.
In addition to supporting our research, the NIH has recognized our excellence in the Biochemistry & Molecular Biology (BMB) and Biophysics, Structural & Computational Biology (BSCB) Ph.D. programs by awarding the university a highly competitive interdepartmental T32 graduate training grant.
The ACE model of care is an evidence-based system designed to prevent patients from experiencing functional decline during hospitalization. At Highland Hospital, we identify patients with certain risk factors at admission, and we target them with specific interventions to preserve or restore physical and mental functioning.